Wei Qiang, Xu Xiao, Ling Qi, Zheng Shusen
Department of Surgery, Key Lab of Combined Multi-Organ Transplantation, Ministry of Public Health, Division of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.
J Res Med Sci. 2013 Aug;18(8):726-30.
This report describes a 66-year-old male who had a long history of hepatitis B virus (HBV) infection. He was found hepatocellular carcinoma (HCC) 5 months after lamivudine resistance mutation and then received a successful hepatectomy. Three years later, hepatitis B envelope antigen seroconversion was achieved and nucleoside analogs were discontinued. After the withdrawn of antiviral treatment, HBV reactivated and acute-on-chronic liver failure (ACLF) occurred. Anti-HBV treatment improved the patient clinical condition. Three months after the remission of ACLF, the patient was diagnosed as HCC recurrence and received another hepatectomy. This case illustrates indefinite duration antiviral therapy and tight viral control should be performed in patients with HBV-related HCC.
本报告描述了一名66岁男性,他有长期乙型肝炎病毒(HBV)感染史。在拉米夫定耐药突变5个月后被发现患有肝细胞癌(HCC),随后接受了成功的肝切除术。三年后,实现了乙肝e抗原血清学转换,核苷类似物停药。抗病毒治疗停药后,HBV重新激活,发生了慢加急性肝衰竭(ACLF)。抗HBV治疗改善了患者的临床状况。ACLF缓解三个月后,患者被诊断为HCC复发并接受了再次肝切除术。该病例表明,对于HBV相关HCC患者应进行无限期抗病毒治疗并严格控制病毒。